Article Information
History
- November 2, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Natalia Espinola, BSc., MSc.1,*,
- Cecilia I. Loudet, MD, MSc1,
- Rosario Luxardo, MD1,
- Carolina Moreno, BSc.1,
- Moe H. Kyaw, PhD3,
- Julia Spinardi, MD, MsC4,
- Carlos Fernando Mendoza, PhD5,
- Carolina M. Carballo, MD6,
- Ana Carolina Dantas, MD6,
- Maria Gabriela Abalos, MD5,
- Jamile Ballivian, MD, MPH1,
- Emiliano Navarro, BSc.1 and
- Ariel Bardach, MD, PhD.1,2
- 1Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Ciudad de Buenos Aires, Argentina
- 2Centro de Investigaciones Epidemiológicas y Salud Pública (CIESP-IECS). CONICET, Ciudad de Buenos Aires, Argentina
- 3Vaccine Scientific Affairs, Pfizer Inc., New York, NY, United States
- 4Vaccine Medical Affairs, Emerging Markets, Pfizer Inc., Itapevi, Brazil
- 5Vaccine HTA, Value and Evidence, Pfizer Inc., Mexico City, Mexico
- 6Vaccine Medical Manager, Pfizer Inc., Buenos Aires City, Argentina
- ↵*Corresponding author: Natalia Espinola, BSc., MSc., Health Technology Assessment and Health Economics Department, Institute for Clinical Effectiveness and Health Policy (IECS), Doctor Emilio Ravignani 2024, Buenos Aires - Argentina, Email: nespinola{at}iecs.org.ar, Phone number: +54 9 221 523 0188
Posted November 02, 2024.
COVID-19 disease and economic burden in adults in six Latin American Countries before nationwide vaccination program: Ministry of Health databases assessment and systematic literature review
